CHESTERFIELD, Mo. — Novus Worldwide Inc. pronounces it has accomplished the acquisition of U.S.-based enzyme firm BioResource Worldwide Inc. (BRI). Underneath the phrases of the settlement, NOVUS turns into the proprietor of all BRI’s merchandise and mental property and takes management of the corporate’s amenities.
“This transfer will permit us to serve our prospects higher and increase our innovation pipeline additional,” mentioned Dan Meagher, NOVUS president and CEO. “Enzymes are very important instruments for producers to make sure animal well being and well-being and assist ship on-farm profitability. We’re very excited to supply our prospects extra choices, in addition to aspire to develop new feed components.”
The connection between the 2 firms isn’t new. NOVUS has partnered with BRI since 2008 to fabricate its protease product, CIBENZA® Enzyme Feed Additive. Meagher says having full possession and management of the product line and the choice to increase NOVUS’ portfolio past protease enzymes is a pure match within the firm’s long-term strategic plans.
“As a frontrunner in clever vitamin, NOVUS’ priorities embrace investing additional in practical proteins and the intestine well being section, rising our portfolio, and attaining stronger management of our provide chain,” he mentioned. “Together with supporting these targets, buying BRI additionally will increase our capabilities to develop modern options within the fermentation area.”
BRI’s merchandise embrace Versazyme® protease feed additive, Xylamax® xylanase feed enzyme, Dymanase® mannanase enzyme, Phytamax® granulated, thermostable, microbial 6-phytase enzyme; and EnzaPro® enzyme and direct-fed microbials, amongst others.
BRI’s co-founder and CEO Dr. Giles Shih, mentioned the acquisition and tapping into the information of workers in each BRI and NOVUS permits for the continued development of the corporate he helped create 25 years in the past.
“We’re tremendous excited in regards to the future the place BRI’s merchandise and folks mix forces with the worldwide attain and deep trade information NOVUS brings to the feed additive area,” Shih mentioned. “This deal will not be one in every of happenstance. Our two firms have labored carefully collectively since 2008 to launch the primary era of heat-stable protease feed enzymes and form how they’re developed, marketed, and optimized so as to add worth to prospects worldwide. This acquisition will allow NOVUS to innovate the subsequent era of proteases and enzymes that can do much more, from selling intestine well being to selling the underside line.”
Together with BRI’s present product portfolio, NOVUS additionally takes over the corporate’s amenities in North Carolina.
Meagher says continuity is vital for present BRI prospects and they need to expertise “enterprise as ordinary” throughout the integration course of.
